Lifesci Capital Has Bullish Outlook for GPCR FY2024 Earnings

Structure Therapeutics Inc. (NASDAQ:GPCR) – Analysts at Lifesci Capital upped their FY2024 earnings estimates for Structure Therapeutics in a report released on Wednesday, November 13th. Lifesci Capital analyst M. Belghiti now anticipates that the company will post earnings of ($0.75) per share for the year, up from their previous forecast of ($0.87). The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.80) per share. Lifesci Capital also issued estimates for Structure Therapeutics’ Q4 2024 earnings at ($0.19) EPS, Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($0.82) EPS.

Several other research analysts have also issued reports on GPCR. Morgan Stanley initiated coverage on Structure Therapeutics in a research report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. Finally, JMP Securities lowered their price objective on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research report on Friday, August 9th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $86.80.

Structure Therapeutics Price Performance

Shares of GPCR opened at $34.17 on Monday. The company has a 50-day simple moving average of $39.38 and a two-hundred day simple moving average of $39.80. The firm has a market capitalization of $1.95 billion, a PE ratio of -46.18 and a beta of -3.23. Structure Therapeutics has a one year low of $26.61 and a one year high of $66.38.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sandia Investment Management LP purchased a new stake in shares of Structure Therapeutics in the second quarter worth $39,000. Assetmark Inc. grew its position in Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after purchasing an additional 719 shares during the last quarter. Quarry LP purchased a new stake in Structure Therapeutics during the 2nd quarter valued at about $79,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Structure Therapeutics by 60.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after buying an additional 1,420 shares during the last quarter. Finally, Dearborn Partners LLC bought a new position in shares of Structure Therapeutics in the third quarter worth approximately $202,000. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.